![]() |
|
|
Vol. 294, Issue 3, 1099-1105, September 2000
College of Pharmacy, University of Tennessee, Memphis, Memphis,
Tennessee (J.A.J., V.L.H., M.S.W.); and St. Jude Children's Research
Hospital and University of Tennessee College of Pharmacy, Memphis,
Tennessee (M.V.R.)
We have previously shown racial differences in propranolol kinetics,
with the largest differences appearing to be in its 4-hydroxylation. The purpose of this study was to identify and confirm the cytochrome P450 enzymes (CYP) with propranolol 4-hydroxylase activity, describe their enzyme kinetics, and determine whether there were racial differences in their catalytic activity. Eleven human recombinant, expressed CYPs were screened, but only CYP1A2 and CYP2D6 possessed propranolol 4-hydroxylase activity. Subsequent studies were conducted in human liver microsomes, including correlation, inhibition, enzyme
kinetics, and racial comparison studies. Significant correlations were
noted between propranolol 4-hydroxylation and
ethoxyresorufin-O-deethylation (marker of CYP1A2
activity), with marked improvement in the correlations when
CYP2D6-mediated propranolol 4-hydroxylation was inhibited with
quinidine. Inhibition studies showed that quinidine inhibited approximately 55% of propranolol 4-hydroxylation and furaphylline (CYP1A2-selective inhibitor) inhibited about 45% of propranolol 4-hydroxylation. Median (range) parameter estimates of
(S)-4-hydroxypropranolol [(S)-HOP]
formation were a Vmax value of 307 (165-2397) and 721 (84-1975) pmol/mg of protein/60 min for CYP1A2 and
CYP2D6, respectively, and a Km value of 21.2 (8.9-77.5) and 8.5 (5.9-31.9) µM for CYP1A2 and CYP2D6,
respectively. CYP1A2- and CYP2D6-mediated propranolol 4-hydroxylation
was about 70 and 100% higher (P < .05 for both), respectively, in African-Americans compared with Caucasians. In summary, we found that both CYP1A2 and CYP2D6 catalyze formation of
4-hydroxypropranolol and that both enzymes exhibited racial differences
in this reaction. The observed racial differences in drug metabolism
may have relevance to drug efficacy, toxicity, or carcinogen activation
for CYP1A2 or CYP2D6 substrates.
This article has been cited by other articles:
![]() |
A. Ohno, Y. Saito, N. Hanioka, H. Jinno, M. Saeki, M. Ando, S. Ozawa, and J.-i. Sawada INVOLVEMENT OF HUMAN HEPATIC UGT1A1, UGT2B4, AND UGT2B7 IN THE GLUCURONIDATION OF CARVEDILOL Drug Metab. Dispos., February 1, 2004; 32(2): 235 - 239. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Lu, M. L. Schrag, D. E. Slaughter, C. E. Raab, M. Shou, and A. D. Rodrigues MECHANISM-BASED INHIBITION OF HUMAN LIVER MICROSOMAL CYTOCHROME P450 1A2 BY ZILEUTON, A 5-LIPOXYGENASE INHIBITOR Drug Metab. Dispos., November 1, 2003; 31(11): 1352 - 1360. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Marcucci, R. E. Pearce, C. Crespi, D. T. Steimel, J. S. Leeder, and A. Gaedigk Characterization of Cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 Activities toward Model CYP2D6 Substrates Dextromethorphan, Bufuralol, and Debrisoquine Drug Metab. Dispos., May 1, 2002; 30(5): 595 - 601. [Abstract] [Full Text] [PDF] |
||||